A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial
NCT00622232
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV Infections
Interventions
GENETIC:
VRX496-transduced autologous CD4 T cells
Sponsor
VIRxSYS Corporation